Form 8-K · Current Report · Filed 2024-02-29
Ionis Pharmaceuticals Announces Key Executive Appointments and Advisory Agreement
Ionis Pharmaceuticals, Inc. announced on February 28, 2024, that Kyle Jenné has rejoined the company as Executive Vice President, Commercial, effective February 29, 2024. Simultaneously, Onaiza Cadoret-Manier, the Executive Vice President, Chief Global Product Strategy and Operations Officer, is leaving the company after serving as an advisor until March 15, 2024. Ionis also entered into an advisory services agreement with Cadoret-Manier, under which she will provide advisory services to the company for a fee through January 10, 2025.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-24-010288
- CIK
- 0000874015
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Financial Statements and Exhibits
Market reaction
Close before filing
$46.54
Next session
-2.3%
Since filing
+11.2%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.